BirdsOfFire
5年前
GOOD NEWS, ADVT IS NOT ON THIS TDA LIST.
I got this info from the UBQU board:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165755423
There is a TDA PDF file listing all the companies that are not up to date on their filings. Apparently, these companies will be put on the expert list. These companies has until the 28th of Sept 2021 to file in order to keep their standing as a pink stock.
AGAIN, ADVT IS NOT ON THE LIST. That means ADVT has been working, behind the scene, to stay up to date and thinking ADVT will rise again, one day, from the ashes.
BirdsOfFire
5年前
I say take no action because the security will still be listed. Even if you want be able to liquidate the asset, there is a slight possibility the ticker might get bought by another company. Second, if you liquidate, you want get anything for your stock. Why bother.
Third, no action ensures there is an official record of your losses. If you took a lost by selling your stock, you will have to have a number of winning stocks to break even. You would also probably have to carry these losses over to the next year.
Fourth, transferring the stock to another brokerage would not be worth it. Cost is the main factor.
IMO,keep your stock.
scoobey-do
5年前
I received the following message from TDAmeritrade today:
Quote:
On September 28, 2021, new amendments adopted by the U.S. Securities Exchange Commission (SEC) go into effect to enhance investor protection and improve issuer transparency. These amendments restrict the ability of market makers to publish quotations for those companies that have not made required current financial and company information available to regulators and investors.
Ahead of the regulatory enforcement date, we will only accept orders to liquidate positions (i.e. no new buy orders) starting August 13, 2021. After the amendment officially goes into effect on September 28, 2021, it may be more difficult to liquidate these securities. Quoting and market liquidity may also be very limited.
What this means for your account(s).
You are receiving this notification because you currently hold one or more of the impacted securities in your account. We're including the list below but be aware that it may not include all of your impacted securities. There is also a chance that the impacted companies could come into compliance with the regulatory requirements ahead of this date and be removed from the list. For a current list of all securities (which is subject to change), please visit www.tdameritrade.com/retail-en_us/resources/pdf/TDA101550.pdf.
You have multiple options to consider, such as:
Take no action. You are not required to sell these securities; however, starting August 13, 2021 we will restrict these securities to liquidation-only transactions. You may continue to hold them, but you may have difficulty selling them in the future and there is no guarantee as to what their future value will be.
Place trades to liquidate. You may place trades to liquidate these securities now. Due to the uncertainly, we cannot guarantee there will be sufficient liquidity to close your position(s) in the future.
Transfer your positions to another financial institution. Other U.S. financial institutions are also impacted by this amendment so you may have difficulty transferring them out of TD Ameritrade. If you are interested in transferring the assets, please submit any outgoing transfers requests to us. (These transactions may incur fees or commissions, depending on the asset type.)
Have Questions? Need Any Help?
We're here for you. Just reply to this message to write us, or call Client Services at 800-669-3900. We're available 24 hours a day, seven days a week.
Sincerely,
TD Ameritrade Client Service
Renee
5年前
ADVT: As of May 25, 2021, TD Ameritrade will restrict orders in Caveat Emptor designated OTC securities to liquidating trades only.
A Caveat Emptor security is a designation the OTC Markets Group places on a security after a determination was made surrounding the company that there may be potential risk to investors which include a questionable stock promotion, known investigation of fraudulent activity committed by the company or insiders, regulatory suspensions, or disruptive corporate actions, among other reasons.
The current list of Caveat Emptor restricted securities is below as of April 12, 2021 and is subject to change at any time.
Please visit www.otcmarkets.com for additional details and real time Caveat Emptor desiginations.
https://www.tdameritrade.com/retail-en_us/resources/pdf/cesecuritylist.pdf
007614100 ADVT Advantis Corporation
scoobey-do
5年前
Happy to see Darren Cherry is still listed as President, Chief Executive Officer & Secretary
Advantis Corp (Grey Market:ADVT)
SECTOR
Distribution Services
INDUSTRY
Medical Distributors
MARKET CAP
$483.2K
Company Description
Advantis Corp. engages in the provision of healthcare products and holistic pain management solutions. Its products is comprised of amster-can premium vapes, gino's roasters, hemperor's club premium vapes, rosin6 rosin press, n2pack and natural elements. The firm focuses on products that supply the medical cannabis, research, and pharmaceutical industries. The company was founded in 1992 and is headquartered in Newport Beach, CA.
Contact Information
Advantis Corp.
1048 Irvine Boulevard
Newport Beach California 92660
P:(949) 354-3585
Investor Relations:
www.advantiscorp.com
Top Executives
Darren Cherry President, Chief Executive Officer & Secretary
Thomas Elgin Chief Medical Officer
Chris Thue Chief Compliance Officer
Woo Kim Director & Director-Media Relations
Jay Ryu Technology Consultant
https://money.cnn.com/quote/profile/profile.html?symb=ADVT
scoobey-do
6年前
SEC Tightens Rule on OTC Issuer Information Disclosure
By Terry Flanagan -September 17, 2020
All it takes is a dollar (stock) and a dream.
That’s the mindset of many — possibly too many — retail investors who trade stocks over the counter. The OTC market is lightly regulated compared with NYSE and Nasdaq, and the securities are speculative. But there’s always the chance that dicey biotech, oil-exploration or cannabis firm that trades at $1 now will be $20 in a year.
The U.S. Securities and Exchange Commission on Wednesday took a step to make the wild west of the OTC market a little less wild by adopting an amended rule that bars broker-dealers from providing public price quotations on companies that have not provided current information about their business or their financials.
In a Wednesday afternoon telephone interview with Traders Magazine, Brett Redfearn, Director of the SEC’s Division of Trading and Markets, said that currently, about 3,000 of the 10,000 companies that trade OTC are in arrears on filing disclosure reports, to the extent that it would preclude broker-dealers from making public markets in their stocks.
“The bottom line is we’re trying to reduce the risk of fraud and manipulation and protect mainstream investors,” Redfearn said. “The idea is to say, “Get that financial information out there if you want to continue to be quoted in the same way.”
“We think this will allow retail investors to make better informed investment decisions, which will aid in reducing fraud in the over-the-counter market,” Redfearn said, citing ‘pump and dump’ schemes and other sketchy activity that tends to happen in OTC.
Redfearn noted that SEC already requires broker-dealers to review basic financial information of a company before initiating OTC price quotations, but there are loopholes such as the “piggyback rule,” which allows broker-dealers to sign off on information received from another broker, rather than directly from the issuer. The rule amendment disallows this by requiring that information come directly from the issuer, and be no more than one year old.
With the amended rule, the SEC has relaxed requirements for certain OTC securities issuers with actively traded securities whose information is more readily available, where there’s less concern about fraud. Also, “we recognize that not all issuers of quoted OTC securities do provide current publicly available financial information, so the commission going forward will consider requests for exemptive relief in certain circumstances,” Redfearn said. “Some of those circumstances could include limiting quoting to a market specifically for sophisticated or professional investors.”
In a release, the SEC said it “adopted amendments to Exchange Act Rule 15c2-11, an important component of the over-the-counter (“OTC”) market regulatory structure. The amendments are designed to modernize the rule, which was last substantively amended nearly thirty years ago, including to recognize advances in communications technologies. The amended rule enhances disclosure and investor protection in the OTC market by ensuring that broker-dealers, in their role as professional gatekeepers to this market, do not publish quotations for an issuer’s security when current issuer information is not publicly available, subject to certain exceptions.”
https://www.tradersmagazine.com/xtra/sec-tightens-rule-on-otc-issuer-information-disclosure/
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Zorro
6年前
tdbowieknife
6年前
georgie18
7年前
メールアドレスで登録
